Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks
Jiajun Xu(University of Glasgow), Reza Akhavan‐Sigari(Medical University of Warsaw)
Cited by 3
Related Papers
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation
|Molecular Cancer|2023|956
Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment
|Cell Communication and Signaling|2023|66